Data from a large cohort of 1,122 diffuse grade II–IV gliomas revealed that IDH-mutant gliomas with high levels of DNA methylation had more favorable clinical outcomes than those with low levels24. The gene discussed is IDH2; the disease is central nervous system cancer.